Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review

Author:

Lominadze Zurabi1ORCID,Hill Kareen2,Shaik Mohammed Rifat3,Canakis Justin P.4,Bourmaf Mohammad2,Adams-Mardi Cyrus4,Abutaleb Ameer5,Mishra Lopa6,Shetty Kirti1

Affiliation:

1. Division of Gastroenterology & Hepatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA

2. Department of Medicine, University of Maryland Medical Center, Baltimore, MD 21201, USA

3. Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, MD 21201, USA

4. Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA

5. Department of Surgery, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA

6. Cold Spring Harbor Laboratory, Feinstein Institutes for Medical Research, Division of Gastroenterology and Hepatology, Northwell Health, Manhasset, NY 11030, USA

Abstract

The emerging field of immuno-oncology has brought exciting developments in the treatment of hepatocellular carcinoma (HCC). It has also raised urgent questions about the role of immunotherapy in the setting of liver transplantation, both before and after transplant. A growing body of evidence points to the safety and efficacy of immunotherapeutic agents as potential adjuncts for successful down-staging of advanced HCCs to allow successful transplant in carefully selected patients. For patients with recurrent HCC post-transplant, immunotherapy has a limited, yet growing role. In this review, we describe optimal regimens in the setting of liver transplantation.

Funder

NIAAA

NCI

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Reference103 articles.

1. Ferlay, J.E.M., Lam, F., Colombet, M., Mery, L., and Piñeros, M. (2023, January 02). All Cancers Fact Sheet. Available online: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf.

2. Epidemiology and Management of Hepatocellular Carcinoma;Kulik;Gastroenterology,2019

3. U.S. Cancer Statistics Working Group (2022, September 11). Cancer Statistics Data Visualizations Tool, Based on 2021 Submission Data (1999–2019): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Available online: www.cdc.gov/cancer/dataviz.

4. A global view of hepatocellular carcinoma: Trends, risk, prevention and management;Yang;Nat. Rev. Gastroenterol. Hepatol.,2019

5. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182–236.

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3